Pharmacological or genetic NEDD4L modulation may be a promising therapeutic strategy that can be considered in the treatment of ischemic diseases, such as myocardial infarction, exacerbation of diabetic retinopathy, and limb ischemia, due to the stimulation of angiogenesis in the ischemic tissues [53]. This evidence concerns the gene NEDD4L and myocardial infarction.